Aytu BioPharma (NASDAQ:AYTU) Posts Earnings Results, Misses Estimates By $0.79 EPS

Aytu BioPharma (NASDAQ:AYTU) released its earnings results on Tuesday. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.79), FiscalAI reports. Aytu BioPharma had a negative net margin of 39.02% and a negative return on equity of 25.06%. The firm had revenue of $15.17 million during the quarter, compared to analyst estimates of $12.17 million.

Here are the key takeaways from Aytu BioPharma’s conference call:

• EXXUA has been commercially launched as the first and only 5-HT1A agonist approved for MDD, positioned as a mechanistically differentiated option with clinical data showing a neutral sexual profile and no clinically meaningful weight gain versus placebo.
• Early commercial traction: prescriptions have been written from 27 states by >100 prescribers, with initial refills and favorable early patient tolerability and satisfaction reported through the RxConnect platform.
• Q2 financials show net revenue of $15.2M (down from $16.2M) and a net loss of $10.6M driven largely by an $8.2M non-cash derivative warrant liability loss; cash was $30M at quarter end.
• The ADHD portfolio remained resilient at $13.2M of net revenue despite de-emphasis and generic entry, aided by RxConnect (≈85% of branded ADHD dispensed) and the company’s authorized generic capturing meaningful share.
• Management trimmed the EXXUA launch budget to under $8M, expects near-term OpEx of ~$4–5M next quarter and estimates company breakeven at ~$17.3M net revenue per quarter, while RxConnect’s 2-month no‑cost access program will cause scripts to grow ahead of reported net revenue early in the launch.

Aytu BioPharma Stock Performance

NASDAQ AYTU opened at $2.35 on Thursday. The firm has a market capitalization of $23.95 million, a P/E ratio of -0.61 and a beta of 0.37. The firm’s fifty day moving average price is $2.52 and its two-hundred day moving average price is $2.35. Aytu BioPharma has a 1 year low of $0.95 and a 1 year high of $3.07. The company has a current ratio of 1.23, a quick ratio of 1.08 and a debt-to-equity ratio of 0.45.

Hedge Funds Weigh In On Aytu BioPharma

Institutional investors and hedge funds have recently modified their holdings of the stock. AWM Investment Company Inc. acquired a new position in shares of Aytu BioPharma in the second quarter valued at approximately $1,351,000. FNY Investment Advisers LLC acquired a new stake in Aytu BioPharma during the 2nd quarter worth approximately $78,000. Stonepine Capital Management LLC boosted its stake in Aytu BioPharma by 75.3% in the 2nd quarter. Stonepine Capital Management LLC now owns 812,676 shares of the company’s stock valued at $1,772,000 after purchasing an additional 348,955 shares during the period. Bellevue Asset Management LLC bought a new stake in Aytu BioPharma in the 4th quarter valued at $65,000. Finally, Two Sigma Investments LP grew its holdings in Aytu BioPharma by 96.2% in the 3rd quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock valued at $129,000 after buying an additional 33,701 shares in the last quarter. 33.49% of the stock is currently owned by institutional investors and hedge funds.

Key Aytu BioPharma News

Here are the key news stories impacting Aytu BioPharma this week:

• Positive Sentiment: Company launched EXXUA (gepirone) extended‑release tablets in December 2025 — management describes EXXUA as the centerpiece of its commercial push into the ~US$22B major depressive disorder market, which supports longer‑term revenue opportunity if uptake builds. Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results
• Positive Sentiment: Revenue held at roughly $15.2M for the quarter and came in at/above some revenue expectations, giving some support that early commercial traction and legacy products still generate sales as the EXXUA launch scales. Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates
• Neutral Sentiment: Balance sheet: company reported approximately $30.0M in cash as of 12/31/2025 — adequate runway for near‑term commercial activity but sensitive to launch burn and working capital needs. Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results
• Neutral Sentiment: Management hosted a conference call and provided a full transcript of remarks and Q&A for investors to assess launch cadence, commercial spend and timing of potential revenue ramp. Aytu BioPharma, Inc. (AYTU) Q2 2026 Earnings Call Transcript
• Negative Sentiment: Big earnings miss on EPS: reported loss of $1.05 per share vs. consensus ≈ ($0.26), a significant downside surprise that drove near‑term negative sentiment. Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates
• Negative Sentiment: Launch investments and commercial build-out increased operating expenses and produced an adjusted EBITDA loss (~$(0.8)M), highlighting near‑term cash burn risk while the company scales EXXUA. Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results
• Negative Sentiment: Market reaction: investors sold after the mixed print and guidance/discussion around launch spend; trading volume was elevated versus recent averages, amplifying downside price pressure. Aytu BioPharma AYTU Q2 2026 Earnings Transcript

Analyst Ratings Changes

AYTU has been the subject of several recent research reports. Ascendiant Capital Markets boosted their target price on Aytu BioPharma from $12.50 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Zacks Research lowered shares of Aytu BioPharma from a “hold” rating to a “strong sell” rating in a research note on Friday, January 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aytu BioPharma in a report on Friday, January 9th. Three investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $9.33.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.